liberte), 90 zotarolimus (ZES; Endeavor) and 421 everolimus eluting stents (EES; Xience-V & Promus). Initial follow-up angiography was performed at 8 months after stenting in all patients, and long-term follow-up angiography at 2 years was performed in patients not exhibiting initial restenosis. Results: The initial restenosis was 23.3% for BMS, 6.7 for SES, 14.8 for PES, 13.3 for ZES and 6.7 for EES. Thus, the restenosis rate of BMS was significantly greater than that in DESs (pϽ0.0001). Interestingly, the initial restenosis of SES and EES were smaller than those of other DESs. In contrast, long-term restenosis were 7.1% for BMS, 10.7 for SES, 7.2 for PES, 4.0 for ZES and 2.9 for EES, yielding no significant differences between them except EES. In late followed study, late loss at 8-months/2-years was 0.76/0.80mm for BMS, 0.18/0.48 for SES, 0.40/0.49 for PES, 0.60/0.43 for ZES and 0.23/0.32 for EES. The serial change of late loss in SES was significantly increased and this increase affected the deterioration of late restenosis in SES.
TCT-639
Background: Compared to larger vessels percutaneous coronary intervention (PCI) of small vessel coronary artery disease presents technical challenges and a greater risk for restenosis, stent thrombosis, and major adverse cardiac events. The long term safety and effectiveness of drug-eluting stents for small vessel lesions therefore remains a concern. Methods: Patients with a broad range of clinical and lesion characteristics undergoing PCI with a Resolute zotarolimus-eluting stent (R-ZES) in small vessels (reference vessel diameter [RVD] Յ2.5 mm) were pooled from 5 trials: RESOLUTE All Comers,: RESOLUTE first-in-human, RESOLUTE International, RESOLUTE Japan, and RESO-LUTE US. Dual antiplatelet therapy was prescribed for 6 months and at operator discretion thereafter. Safety and effectiveness endpoints; target lesion failure (TLF; composite of cardiac death [CD] , target vessel myocardial infarction [TVMI] , or clinically-driven target lesion revascularization [TLR]), CD, TVMI, CD or TVMI, TLR, and definite or probable stent thrombosis (ST) were compared between patients with small and large vessels (RVD Ͻ2.5 mm) after propensity score adjustment for differences in baseline characteristics. Results: There were 1956 patients (38.1%) with a RVD Յ2.5 mm and 3174 patients (61.9%) with RVD Ͻ2.5 mm. Most baseline characteristics were significantly different between the 2 groups; small vessel patients were older with a higher proportion of females and had higher rates of diabetes, prior PCI, hypertension, hyperlipidemia, and multivessel disease. 
Conclusions:
After adjustment for differences in baseline characteristics there are no significant differences in safety and effectiveness outcomes to 2 years between patients with large and small vessel disease. The rates of CD, TVMI and ST provide evidence for the long-term safety of R-ZES in patients regardless of RVD. Background: Recent data suggest that late or very late stent thrombosis (ST) is associated with lower in-hospital mortality than early ST, but data on longer-term outcomes is lacking. Methods: Data from the VHA Cardiovascular Assessment, Reporting, and Tracking (CART) Program was used to identify all presentations of angiographic ST with known timing between 2006-2011 at 76 VA hospitals. In accord with the Academic Research Consortium (ARC) standards, cases occurring Ͼ 30 days after stent implantation were defined as early; 31-365 days as late; and Ͻ 365 days as very late. Cox-proportional hazard regression modeling with backwards covariate selection was used to describe differences in mortality rates after ST. Results: A total of 448 patients with ST and known time from initial stent implantation were identified. The cohort consisted of 124 (28%), 96 (21%), and 228 (51%) patients with early, late and very late ST, respectively. Late and very late ST were associated with lower crude mortality than early ST at both 30-days and 90-days (Figure) . On multivariate modeling, patients with very late ST had significantly lower 30-day mortality (HR 0.3, [95% CI 0.13-0.68]) when compared to patients with early ST. Similar trends were also observed for late ST compared to early ST. Conclusions: Long term mortality risk following an angiographic ST presentation differs as a function of time from index PCI to ST, potentially reflecting the differing mechanisms of ST that predominate at different timeframes. Specifically, ARC very late ST is associated with lower mortality at 30 days when compared to early ST.
TCT-641
The effect of balloon angioplasty compared with drug-eluting stent (DES) implantation for the treatment of DES in-stent restenosis. Toyohashi Heart Center, Toyohashi, Aichi, Japan Background: There are no observational studies directly comparing the safety and efficacy of balloon angioplasty (POBA) versus DES for treatment of DES in-stent restenosis (ISR). Methods: We examined data on all patients who underwent percutaneous coronary intervention (PCI) for ISR at Toyohashi Heart Center between 01/2004 and 05/2012. We compared the efficacy of DES to balloon angioplasty for treating DES ISR. Results: Of the 9126 patients who underwent PCI treated with DES over 8 years, 512 had DES ISR and met our study criteria. Of the 353 patients with DES ISR, were treated with balloon angioplasty and 129 with DES. At 1-year angiographic follow-up (follow-up rate: 73%), in-stent restenosis was observed in 117 cases in the POBA group and 28 cases in the DES group (45% vs. 30%; P ϭ 0.017). In a comparison between treatments using a cutting balloon vs. a conventional balloon, there was no significant difference observed in the rate of angiographic restenosis. Conclusions: In our analysis of patients with DES ISR, DES use was associated with a significantly lower rate of ISR or TLR when compared to POBA. 
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